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Behc¸et’s disease (BD) is a multisystemic disease that may involve all systems, the most
common symptoms being oral and genital ulcerations and ocular involvement. Pulmonary
involvement is not usually investigated in BD unless there is a specific complaint. In this study,
pulmonary parameters and findings were investigated in BD patients at periodic follow-ups. A
total of 112 subjects with a definitive diagnosis of BD from the Ocular Diseases Polyclinic, Beh-
c¸et Disease Center, Ankara Training and Research Hospital and who had been referred to the
Thoracic Diseases Polyclinic between JanuaryeOctober 2010 were evaluated. In the patients,
the absence of active smoking, pregnancy, lactation and systemic steroid use were especially
considered. A total of 112 patients between 14 and 61 years-old (53 male, 59 female) were
enrolled in the study. The duration of follow-up varied between 1 and 22 years. The most
commonly encountered symptom was hemoptysis observed in 18 subjects. 43 patients had mild
obstruction, 9 patients had moderate obstruction, 4 patients had advanced obstruction and 4
patients showed restrictive alterations. Thoracic CT was normal for 83 subjects. Pulmonary
involvement was observed as a pulmonary artery aneurysm in 4 patients and was treated. In
BD, although anyone of PFT and CT values is normal, others may show pathological values.
We believe that it would be useful in the follow-up to keep a regular record of the patient data
and to perform PFT and, if possible, CT periodically.
ª 2012 Published by Elsevier Ltd.Introduction dermatological, cardiovascular, pulmonary, central nervousThree major symptoms for Behc¸et’s Disease (BD) are uveitis,
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2 Published by Elsevier Ltd.system and gastrointestinal system involvements, epididy-
mitis and arthritis.1e5 Pulmonary involvement is not
commonly investigated in BD, unless symptoms are detected
Systemic and pulmonary screening of patients with Behcet’s disease 467according to the clinical history of the patient. In the 1960s,
although pulmonary findingswere highlighted, knowledge on
this issue remained limited.6,7 Pulmonary involvement,
which is a rare form of vasculitis and has a ratio of diagnosis
around 1e16% in BD, is one of the major complications with
the highest mortality rate.8e10 Arterial and venous throm-
bosis, hemorrhaging, pulmonary infarctions, recurrent
pneumonia, pulmonary fibrosis, obstructive and restrictive
pulmonary diseases, pulmonary vasculitis and aneurysmmay
be seen in addition to pulmonary involvement, which could
lead to the formations of arterial aneurysm, and broncholitis
obliterans.2,11e14 Although pulmonary artery aneurysm is
a very rarely occurring disease, due to its poor prognosis and
high mortality, it seems that much more attention should be
paid to this issue.2,5,15 In this study, the evaluation of
pulmonary functions and pulmonary parenchymal involve-
ment was completed using pulmonary function tests (PFT)
and thoracic computed tomography (CT), respectively. The
correlation of the findings with disease activity in BD was
examined.
Methods
Since 1998, in the Behc¸et’s Disease Center of Ankara
Training and Research Hospital, patients with BD have been
diagnosed and multisystemically examined and treated.
After approval for the study from the hospital Ethics
Committee, the subjects with Behc¸et’s Disease in the
Ophthalmology Clinic between JanuaryeMay 2011 were
retrospectively evaluated in the Pulmonary Diseases Clinic
for a periodic follow-up. The criteria for diagnosis were
determined according to the protocols in the International
Study Group for BD (1990). In the study, a total of 112
patients, 59 female (mean age 31.9  9.0 years) and 53
male (mean age 30.6  9.2 years), were evaluated. None of
the patients had significant findings or a clinical history of
the pulmonary system. In addition, the absence of active
smoking, pregnancy, lactation and systemic steroid use
were specifically considered in the patients. Age and onset
age, gender, duration of the disease, cardiovascular,
pulmonary and other systemic findings related to the
disease, and examinations with chest X-Ray and thoracic CT
were included in the evaluated parameters. The PFT of all
patients was applied by spirometry. PFT was measured by
Vmax: 25 Sensor Medics Cardiopulmonary Exercise Testing
Instrument with the patients in a sitting position. ToTable 1 Frenquency of clinical manifestations and genetic in B
Female
n %
Oral ulcers 59 100
Genital ulcers 51 86.4
Erythema nodosum 18 30.5
Papulo-pustular lesionsa 21 35.6
Eye lesionsa 34 57.6
Pathergy test (þ)a 17 28.8
Family story 24 40.7
HLA e B51 (þ) 4 6.8
a p < 0.05.determine the impairment of air flow by PFT, forced expi-
ratory volume in 1 s (FEV1) (L), forced vital capacity (FVC)
(L), FEV1/FVC ratio (%), forced mid expiratory flow
(FEF25e75) (L/s) and peak expiratory flow (PEF) (L/min)
were measured. Normal ranges were accepted as those
previously outlined in the Turkish Thoracic Society Criteria
(2000) in the evaluation of PFT. Thoracic CT examinations
were performed by spiral volumetric technique using the
Pronto-Hitachi device. Technical parameters were chosen
as 10 mm table movement, 120 kV, 150 mAs, 10 mm section
thickness and filter 3 and 2H. The images were obtained
with a 512  512 matrix. A window width (WW) of 300 and
a window level (WL) of 50 Haunsfield units (HU) were
determined for soft tissues, and a window width (WW) of
1200, and a window level (WL) of 600 HU were determined
for pulmonary parenchymal structures for the evaluation.
Statistical tests
Statistical analyses were performed using Statistical Package
for Social Sciences 12 (SPSS 12). Frequency and percentages
of the data were determined and overall data were
compared using the ManneWhitney U test between two
groups. The variables were compared using Chi-squared tests
and values of p < 0.05 were considered to be significant.Results
The 112 patients enrolled in this study were divided into
two groups: 59 (52.7%) females and 53 (47.3%) males. The
mean age of the patients was 31.3  9.1 years (mean  SD),
onset age of the disease was 23.7  8.2 years (mean  SD)
and length of follow-up was 5.6  5.0 years (mean  SD).
Significant differences were not found between the genders
in terms of age, length of follow-up and onset age of the
disease (p > 0.05). Data according to gender, lesions,
familial relation and genetic predisposition are shown in
Table 1 and the rate of systemic involvement is shown in
Table 2. As seen in Table 1, papulo-pustular lesions were
found to be significantly higher in the male group (56.6%)
compared to the female group (35.6%) (p < 0.05). Similarly,
the incidence of uveitis was found to be significantly higher
in the male group (79.2%) than the female group (57.6%)
(p < 0.05). Data in Table 2 show that the rate of arthritis
was significantly higher in the male group (45.3%) than theD.
Male Total
n % n %
53 100 112 100
41 77.4 92 82.1
23 43.4 41 36.6
30 56.6 51 45.5
42 79.2 76 67.9
11 20.8 28 25.0
16 30.2 40 35.7
3 5.7 7 6.3
Table 2 Systemic involvement in BD (except pulmonary
involvement).
Female Male Total
n % n % n %
Vasculara,b 5 8.5 7 13.2 12 10.7
Neurological 2 3.4 1 1.9 3 2.7
Gastrointestinal 1 1.7 0 0 1 0.9
Arthritisb 13 22.0 24 45.3 37 33
a 9 deep vein thrombosis, 2 cavernous sinus thrombosis, 1
superior vena cava thrombosis.
b p < 0,05.
468 G. Bilgin et al.female group (22%) (p < 0.05). Significant differences were
not found for the other systemic involvements. The most
commonly encountered symptom was hemoptysis, which
was observed in 18 subjects (16.1%). Hemoptysis, shortness
of breath, cough, chest pain and pleural pain did not reveal
any significant difference in terms of gender (P > 0.05)
(Table 3). Although PFT results were normal in 56 patients,
43 patients had mild obstruction, 9 patients had moderate
obstruction, and 4 patients had severe obstruction (Table
4). Thoracic CT was normal in 83 (74.1%) subjects. In 29
(25.9%) subjects, pulmonary lesions were observed and are
shown in Table 5. Pulmonary involvement was observed in
four patients in the form of a pulmonary artery aneurysm
and was treated using the therapeutic agents commonly
used in the treatment of BD. The most common choice of
treatment for the enrolled patients was colchicine. The use
of colchicines in the treatment was significantly higher in
the female group (84.7%) compared to the male group
(35.8%) (p < 0.01).Discussion
BD was defined in 1937 by Hulusi Behc¸et, a Turkish
dermatologist. whose work on the subject is well known,
especially in Mediterranean, Middle Eastern and Asian
countries.4,16 The highest prevalence rate has been re-
ported from Turkey as 80e370 per 100,000 population. In
general the onset age of the disease is determined as the
second or third decade of life. Male to female ratio is re-
ported to be almost similar. However, the disease runs
a severe course in men compared to women and with onset
before 25 years of age.4,5 In this study, the mean age of
onset of the disease was 23.7  8.2 years (23.8  8.9 yearsTable 3 Pulmonary symptoms in BD.
Female Male Total
n % n % n %
Hemoptysisa 9 15.3 9 17 18 16.1
Dyspnea 5 8.5 8 15.1 13 11.6
Cough 3 5.1 5 9.4 8 7.1
Chest pain 1 1.7 5 9.4 6 5.4
Pleural pain 2 3.4 3 5.7 5 4.5
a 4 massive hemoptysis.in males and 23.5  7.6 years in females). No significant
difference was found in terms of age at onset of the disease
(P > 0.05). Tursen et al. evaluated clinical findings
according to gender and found that pulmonary involvement
was markedly higher in males compared to females.17 In the
research of Uc¸an et al., the rate of pulmonary involvement
in the male population was found to be 94%.18 Similarly, in
this study, 3 of 4 patients with pulmonary artery aneurysm
were male. In addition for all patients with BD, the rate of
men was 47.3% and no significant difference was found
between the genders (p < 0.05). Although it has been
suggested that immunity, infections and genetic factors
play an important role in the pathogenesis of the disease,
the etiology of the disease, however, is still not clearly
known.3,4,11 BD is strongly associated with HLA-B51, and
this relationship has been confirmed in different ethnic
groups.19 In this study, the genetic background of 90 of the
112 subjects was not known. When the other 22 subjects
were examined, no significant difference was found for
HLA-B51 positivity in terms of gender (p > 0.05). However,
four of the patients with pulmonary artery aneurysm were
HLA-B51 (Table 1). Familial aggregation has been noted in
BD for a period that has a high value of 11.4  52.5 in
Turkey.19 Most of the families containing multiple cases of
BD did not show a particular pattern through Mendelian
inheritance. Throughout the evaluation of the familial
histories, despite the lack of difference by gender
(p > 0.05) (Table 1), 3 of 4 patients with pulmonary artery
aneurysm had positive family histories. In BD, neutrophile
hyperfunction plays an important role in the occurrence of
the symptoms. It has been reported that when the release
of the amount of free oxygen radicals increases from the
neutrophiles, acute inflammatory tissue damage occurs,
resulting in superoxide damage in the respiratory pathways,
which leads to pulmonary involvement.20 In addition, it is
also known that non-specific inflammation observed during
BD causes hyper-reactivity of the bronchial tree.21 Char-
acteristics of BD are recurrent, and may continue for
a couple of days to several weeks or months, and over
longer time periods, permanent tissue damage or chroni-
cally repeating symptoms may be observed with the
subsequent risk of mortality.19 Hemoptysis is the most
commonly encountered finding of pulmonary involvement.
Uc¸an et al. mentioned hemoptysis as the most important
symptom (64%) of all.18 In this study, the rate of hemoptysis
was found to be 18 (16.1%) (Table 3). Other symptoms of BD
were repetitive episodes of dyspnea, cough, chest pain,
pleural pain, increased sedimentation rate and
anemia.3,4,16 Systemic findings such as fever and sweating
may be commonly seen through the development of
pulmonary artery aneurysms.3 Four subjects in this study
with aneurysm had all these findings. However, it has also
been reported that pulmonary artery aneurysms might be
the first and the only symptom of the disease, as an
incomplete form.3,22 In BD, although artery involvement is
more rare than venous involvement, the outcomes of artery
involvement are much more serious. The aorta is the largest
and most important artery of the body, followed by the
pulmonary, femoral, popliteal and carotid arteries.5 The
pulmonary manifestations of BD include pulmonary
infarcts, pulmonary hemorrhage, atelectasis, cryptogenic
organizing pneumonia, eosinophilic pneumonia, recurrent
Table 4 Pulmonary function tests in BD (mean  SD).
FVC (L) FEV1 (L) FEV1/FVC (%) PEF (L/min) FEF25e75 (L/s)
Normal 3.1  0.7 2.5  0.6 98.6  7.7 5.3  1.5 2.8  0.9
Mıld 2.5  0.8 1.9  0.5 96.0  9.1 4.6  1.4 1.8  0.6
Moderate 1.6  0.5 1.2  0.4 90.9  17.8 2.3  1.1 1.1  0.7
Severe 0.9  0.6 0.6  0.2 89.3  29.8 1.2  0.7 0.5  0.1
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vasculitis and thrombosis of pulmonary vessels result in
infarction, hemorrhage, and focal atelectasis. The most
common parenchymal lesions are subpleural alveolar infil-
trates and wedge-shaped or ill-defined rounded areas of
increased opacity, which represent focal vasculitis with
hemorrhage, infarction and inflammation.23
Pneumonia in BD can be the result of inflammation of
pulmonary parenchymal vessels or may occur secondary to
immunosuppresive therapy.
Damaged lung tissue can be replaced by fibrosis or
emphysema. Focal or diffuse air trapping may result from
airway obstruction due to small airway inflammation and
fibrosis.
Vasculitis of the pleura may result in the formation of
pleural nodules, which are often difficult to differentiate
from parenchymal subpleural lesions.
Mediastinal lymphadenopathy may be seen and is prob-
ably a reaction to an inflammatory process in the chest. An
inflammatory process in the mediastinum may manifest as
a mediastinal mass.23Conclusions
BD involving the chest can manifest as a wide spectrum of
abnormalities. Aneurysms of the pulmonary arteries with or
without thrombosis are a typical manifestation of BD.
Involvement of the SVC and aorta may occur, and pulmo-
nary findings include pulmonary hemorrhage and atelec-
tasis, fibrosis, and air trapping. The mediastinum and
pleura may also be involved.3,22 In this study, four subjects
were diagnosed with pulmonary arterial aneurysm and were
treated accordingly. The main histological feature of
pulmonary involvement is non-specific vasculitis, which
may be seen on arteries and veins of any diameters.
Vasculitis has three different forms: venous occlusion and
varicosis, arterial occlusion and the formation of arterialTable 5 Thorax CT findings in BD.
Female
n
Pulmonary artery aneurysm 1
Pulmonary nodule 7




Emphysematous appearance 3aneurysm. Histological features of the wall of an aneurysm
involve dense inflammation and are filled with neutrophils,
lymphocytes in media and adventitia during the active
stage, and rupture in internal and external elastic lamina,
fibrous thickening in intima and adventitia, and destruction
of media and the obstruction of vasa vasorum at a later
stage.5,22,24 Pulmonary infiltration, atelectasia, wedge or
longitudinal shadowing, pleural effusion, subpleural mass,
nodular and reticular opacities, aneurysms of aorta and
pulmonary artery, hillar distension and pleural thickening
have been seen as the findings on chest X-Ray imaging of
the patients with BD.3,16,25 When any pathology is sus-
pected in the evaluation of the chest X-Ray of the patients
with BD, PFT, thoracic CT and scintigraphy are recom-
mended.8,9,25,26 Occasionally, these tests may also be per-
formed before a diagnosis of pulmonary involvement, but
the studies on this aspect of the disease are very
limited.23,27,28 Few studies have reported that pulmonary
functions changed before clinical findings of pulmonary
disease occurred.6 In a study by Uysal et al., the percentage
of FEV1 values to the expected values were found to be low
in the patient group compared to the control group.16 This
result showed that there was a partial pulmonary involve-
ment in the patients with BD. Tekin et al. stated that 35.7%
of subjects had normal and 64.3% had obstructive results in
their study.2 In another study of Uysal et al. on women with
BD without any pulmonary findings, no correlation could be
found between parenchymal changes that were detected
by using high resolution computed tomography (HRCT) and
PFT.16 FEV1 level was used in order to detect obstruction in
PFT. According to the FV1 level, obstruction was 100e80%
normal, 80e60% mild, 60e40% moderate, and 40-20%
severe. In this study, the results of PFT for 56 (50.0%)
patients were normal (Table 4). It was determined that
gender and PFT were irrelevant but FEV1 was significantly
high in females. A total of 112 patients, 59 female FEV1(L)
2.3  0.6(mean  SD) and 53 male FEV1(L) 1.9  0.8
(mean  SD) were evaluated (p < 0.05).Male Total
% n % n %
1.7 3 5.7 4 3.6
11.9 4 7.5 11 9.8
15.2 9 17.0 18 16.1
0 3 5.7 3 2.7
3.4 0 0 2 1.8
3.4 2 3.8 4 3.6
5.1 3 5.7 6 5.4
470 G. Bilgin et al.In our patients, no pulmonary disease was present that
could lead to any pulmonary restriction, COPD, or asthma.
We concluded that though there is a pulmonary restric-
tion in BD, this restriction bears no relation to pulmonary
functions.29 It would be useful to perform PFTs in patients
with BD, both with or without any pathological findings on
CT to obtain information about pulmonary functions. An
obstruction in BD may be bronchial hyper-reactivity.
It is known that the damage of pulmonary pathways is
caused by the disease; however, four subjects (3.5%) with
pulmonary artery aneurysm showed an advanced obstruc-
tion, even though they were not smokers (Table 5).
Although chest radiography is commonly used for initial
assessment, CT can demonstrate the entire spectrum of
thoracic manifestations of BD. It is noninvasive and
provides excellent delineation of the vessel lumen and wall
and perivascular tissues as well as detailed information
concerning the lung parenchyma, pleura, and mediastinal
structures.23
CT is helpful in the diagnosis and follow-up of aneurysms
and thrombosis in BD. It can show the small differences in
attenuation that may result from airway obstruction in
patients with BD. Parenchymal changes may correspond to
perianeurysmal consolidation and air-space nodules
observed on CT.30 It frequently shows small subpleural
hyperlucent areas in patients with BD.
In general, no pathological finding was obtained from the
results of chest X-Ray and CT imaging of almost all the
patients in this study, although there were significant
decreases in PFT values,which highlighted the importance of
PFT in BD. A change in pulmonary functions without any
clinical features of the disease is rare. There are few studies
which have reported unseen pulmonary parenchymal
changes and some lesions which may have been overlooked
on the chest X-Ray may be detected on thoracic CT, which is
an important method with which to diagnose pulmonary
involvement and to monitor responses to therapy. Ate-
lectasia, loss of volume, wedge or longitudinal shadowing,
and nodular or reticular opacities are parenchymal changes
seen in patients with BD, regardless of the presence of
a pulmonary artery aneurysm. Therefore, in this study, each
patient was evaluated after chest X-Ray and tomography
imaging. The results obtained from CTwere normal in 74.1%
(Table 5). Angiography and venography are known as other
methods for diagnosis of BD. Angiographic studies performed
using a contrast substance revealed the development of
thrombus and aneurysms, and the rupture of pre-existing
aneurysms. However, if there is a complete obstruction
due to thrombus, it can not be demonstrated by angiography.
In the last decade, non-contrast MRA has been the most
preferred diagnostic tool to scan the changes in the superior
vena cava, aorta and pulmonary arteries.3,25 Pulmonary
perfusion scintigraphy performed using Technicim-99-
macroaggregate albumin (99mTc-MAA) has been found to
be successful in the demonstration of vasculitis and inflam-
mation lesions.9 In a study performed on 25 patients with BD
by U¨nlu¨ et al., scintigraphic examination was performed
using 123 meta-iodobenzylguanidine (123 I-MIBG) and was
beneficial in the determination of minimal endothelial
lesions located in the lungs, thus, it may be used as a prog-
nostic marker in further studies.31 It is possible to eliminate
all of the pulmonary artery aneurysms using medicaltherapies. Medical therapy is believed to be efficient
throughout the acute phase, although it has been observed
that the local inflammatory process occurs just before the
formation of fibrosis, thus proving the elimination of
inflammation.1,3,22,32 In the treatment of vasculitis, cyclo-
phosphamide and corticosteroid application has been effi-
cient as medical therapy and in providing radiological
remission.1,30 Tunacı A., Erkan F. et al. reported that use of
corticosteroid and cyclophosphamide eliminated pulmonary
artery aneurysms or reduced the dimensions of the aneu-
rysm.3,33 However, there is also a high risk of mortality in
such cases.5 A long-term follow-up is required for potential
recurrences after the cessation of the medical therapy. In
the cases of this study, colchicines were mostly used, fol-
lowed by aso, csa, leukeran, interferon, endoxane and in
some cases, a combination of these was applied. When
medical therapy fails, or complications such as major
hemoptysis occur, embolization is indicated for bilateral,
multiple aneurysms. Mouas et al. reported that they
successfully embolized a bilateral aneurysm in a young
patient.34 However, embolization may be challenging as the
majority of cases have vessels with thrombosis and occlu-
sion. Thus, surgical therapy is not administered in all cases.
However, the recurrences seen in the areas of vascular
anastomosis, due to the fragile structure of the vessels, and
the risks of post-operative,massive, fatal hemoptysis is quite
high. As a result, surgical therapy should be considered in
patients who do not respond to medical therapy or emboli-
zation, and/or in patients withmassive hemoptysis.22,34,35 In
this study, one out of four patients was successfully operated
on. The medical therapy of all the patients is ongoing.
In conclusion, it can be said that although pulmonary
involvement in BD is rare, it is fatal. Specific findings on CT
may occur anytime indicating the trend of the disease and
giving valuable hints. When PFT and thoracic CT values are
normal, the other examinations may show pathological
values through the diagnosis. Thus, it is believed that
maintaining a regular record of patient data and performing
PFT and, thoracic CT, where possible, periodically (once
a year) would be beneficial in patient follow-up.Conflict of interest statement
None declared.References
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